Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-210-6248
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees8
OptionableNot Optionable
MOTIF BIO PLC/S (NASDAQ:MTFB) Frequently Asked Questions
What is MOTIF BIO PLC/S's stock symbol?
MOTIF BIO PLC/S trades on the NASDAQ under the ticker symbol "MTFB."
When is MOTIF BIO PLC/S's next earnings date?
What price target have analysts set for MTFB?
3 equities research analysts have issued 12 month target prices for MOTIF BIO PLC/S's shares. Their forecasts range from $32.00 to $32.00. On average, they anticipate MOTIF BIO PLC/S's stock price to reach $32.00 in the next year. This suggests a possible upside of 1,089.6% from the stock's current price. View Analyst Price Targets for MOTIF BIO PLC/S.
What is the consensus analysts' recommendation for MOTIF BIO PLC/S?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MOTIF BIO PLC/S in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MOTIF BIO PLC/S.
Has MOTIF BIO PLC/S been receiving favorable news coverage?
News headlines about MTFB stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MOTIF BIO PLC/S earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of MOTIF BIO PLC/S's key competitors?
Some companies that are related to MOTIF BIO PLC/S include Poxel (PXXLF), Mersana Therapeutics (MRSN), BioXcel Therapeutics (BTAI), Aquestive Therapeutics (AQST), Proteostasis Therapeutics (PTI), Ocular Therapeutix (OCUL), CytoDyn (CYDY), Syndax Pharmaceuticals (SNDX), Menlo Therapeutics (MNLO), Adamis Pharmaceuticals (ADMP), Marinus Pharmaceuticals (MRNS), AgeX Therapeutics (AGE), BELLUS Health (BLUSF), Axovant Sciences (AXON) and Imprimis Pharmaceuticals (IMMY).
Who are MOTIF BIO PLC/S's key executives?
MOTIF BIO PLC/S's management team includes the folowing people:
- Mr. Graham George Lumsden, CEO & Exec. Director (Age 59)
- Mr. Jonathan E. Gold, CFO & Exec. Director (Age 46)
- Dr. David B. Huang, Chief Medical Officer (Age 44)
- Mr. Robert Dickey IV, Advisor (Age 63)
- Liam O'Donoghue, Company Sec.
When did MOTIF BIO PLC/S IPO?
(MTFB) raised $17 million in an IPO on Friday, November 18th 2016. The company issued 2,400,000 shares at a price of $6.98 per share. H.C. Wainwright & Co. served as the underwriter for the IPO.
Who are MOTIF BIO PLC/S's major shareholders?
MOTIF BIO PLC/S's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Jane Street Group LLC (0.09%).
Which major investors are buying MOTIF BIO PLC/S stock?
MTFB stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC.
How do I buy shares of MOTIF BIO PLC/S?
Shares of MTFB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MOTIF BIO PLC/S's stock price today?
One share of MTFB stock can currently be purchased for approximately $2.69.
How big of a company is MOTIF BIO PLC/S?
MOTIF BIO PLC/S has a market capitalization of $39.88 million. The company earns $-44,810,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. MOTIF BIO PLC/S employs 8 workers across the globe.
What is MOTIF BIO PLC/S's official website?
How can I contact MOTIF BIO PLC/S?
MOTIF BIO PLC/S's mailing address is 125 Park Avenue 25th Floor, New York NY, 10011. The company can be reached via phone at 212-210-6248 or via email at [email protected]
MarketBeat Community Rating for MOTIF BIO PLC/S (NASDAQ MTFB)
MarketBeat's community ratings are surveys of what our community members think about MOTIF BIO PLC/S and other stocks. Vote "Outperform" if you believe MTFB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days.
